Considerations in the Management of Actinic Keratosis: The Importance of Adherence and Persistence to Therapy

Justin W. Marson, MD¹, James Q. Del Rosso, DO², Neal Bhatia, MD³, Darrell S. Rigel, MD, MS⁴

¹National Society for Cutaneous Medicine, New York, NY
²JDR Dermatology Research/Thomas Dermatology, Las Vegas, NV
³Director of Clinical Dermatology, Therapeutics Clinical Research, San Diego, CA
⁴Department of Dermatology, NYU Grossman School of Medicine, New York, NY

ABSTRACT

Background: Actinic keratosis (AK) is a pre-malignant lesion with a poorly defined risk of progression to invasive squamous cell carcinoma (SCC). AKs are also associated with increased future risk of invasive SCC. However, there are many barriers to therapy adherence that may affect long-term treatment efficacy.

Objective: To review the current literature reporting known factors of AK treatment non-adherence intrinsic to patient behavior and treatment regimens and re-examine how dermatologists can navigate these challenges.

Methods: A Medline literature search was performed to identify existing evidence regarding barriers to adherence with AK treatment regimens intrinsic to patient behavior, patient counseling, and treatment regimens pertinent for review.

Results & Discussion: Factors intrinsic to prescribed patient-applied therapy that can exacerbate non-adherence include: 1) length of treatment duration, 2) frequency of application, 3) complexity of treatment regimen, 4) duration and 5) severity of local skin reactions (LSR) and adverse reactions. Novel mechanisms of action that induce cellular apoptosis (as opposed to necrosis) via inhibition of tubulin polymerization and cell cycle arrest, may promote treatment regimen adherence and long-term outcomes. Dermatologists should also be conscious of how they counsel patients as insufficient counseling may also lead to poor adherence.

Conclusion: Dermatologists must understand the value of shorter course therapies and their positive impact on adherence and be well-versed in the mechanisms, efficacy and adverse events associated with treatment options. By doing so, dermatologists may best counsel and educate patients and devise regimens that address individualized patient concerns.

INTRODUCTION

Adherence can be defined as how closely a patient follows and executes a prescribed treatment regimen.¹⁾²⁾ This includes (but is not limited to) factors such as obtaining the medication, completing the entirety of a treatment course (persistence), utilizing the medication at the appropriate frequency and dose, and properly implementing the route/location of administration.¹⁾⁴⁾ Even after successfully obtaining a medication, adherence can be compromised by the
length of treatment, the complexity of a regimen, perceived (relative) lack of improvement, as well as duration and severity of adverse events, such as local skin reactions.\textsuperscript{3,4} Unfortunately, in a real-world setting, a patient’s adherence to therapy is as important, if not more so, than the efficacy and mechanism of action of the chosen regimen in achieving optimal long-term outcomes. These barriers can be amplified when managing chronic dermatoses as patients must adhere to repeated, regular treatments over the course of months or years. Furthermore, future repeat cycles of therapy may be negatively impacted by current severe local skin reactions. These negative experiences may color patients’ perceptions of AK management and affect their risk-benefit analyses future therapy.

Actinic keratoses (AK) are likely one of the most prevalent skin diseases treated by dermatologists, accounting for over 14% of all dermatology visits and upwards of $3.1 billion in annual healthcare expenditures.\textsuperscript{5,6} These pre-malignant lesions arise from decades of actinic and ultraviolet damage leading to field cancerization. The presence of a single AK therefore likely suggests the presence of many subclinical actinic keratoses in evolution. AKs are also known to have the potential to progress into invasive cutaneous squamous cell carcinoma (cSCC).\textsuperscript{7-11} Unfortunately, there are no universally accepted clinical factors and few histopathological signs to indicate which AK has the 0.025-16%\textsuperscript{12} risk of progression to invasive SCC and therefore all AKs require medical evaluation and management.

Because of the chronic nature of AK pathophysiology as well as the need for their treatment, long-term efficacy of therapy relies not only on mechanism of action but also the adherence to the prescribed treatment regimen.

### METHODS

A review of the literature pertaining to the epidemiology, natural history, prognosis, management of AK as well as the mechanism of action of and adherence to current and impending patient-applied AK therapy was conducted. The goal of this search was to evaluate the literature for barriers to adherence intrinsic to patient behavior, patient counseling, and treatment regimens. The Medline database was queried for all relevant articles published between 1980 and 2021 using exploded MeSH terms and keywords pertaining to the following themes: diagnosis, prognosis, and epidemiology, risk factors, squamous cell carcinoma, therapy. The Boolean term “AND” was used to find the intersection of these themes with the term “actinic keratosis.”

### RESULTS & DISCUSSION

**The State of Patient-applied Field Therapy for Actinic Keratoses**

Aside from prevention and sun-protective measures, there are two overarching principles for treating AKs: lesion-directed therapy and field therapy.\textsuperscript{13} Lesion-directed therapy are office-based, dermatologist-administered treatments such as cryosurgery, surgery, chemical peel, or laser that primarily target single, clinically visible AKs.\textsuperscript{14,15} These treatments are often complemented and augmented by field therapy such as photodynamic therapy (PDT) or at-home, patient-applied therapies that treat both clinically-visible and subclinical AKs.\textsuperscript{3,4,14-16} Field therapy is important in managing AKs between office visits given the likelihood of subclinical...
lesions in the setting of field cancerization and chronic nature of AKs and actinic damage.\textsuperscript{17-20} Current field-therapies rely on either disrupting cell signaling, halting cellular division or stimulating the immune system to detect and destroy atypical cells.\textsuperscript{21} While there are multiple pathways that these therapies utilize, they function by either primarily or secondarily stimulating local (and in the case of imiquimod, also systemic) inflammation.\textsuperscript{14,21} Agents such as 5-fluorouracil (5-FU), which interferes with DNA replication, applied over 2-6 weeks, can induce significant inflammation, leading to cellular necrosis, to treat AKs.\textsuperscript{14,22,23} In a less severe fashion, imiquimod, which augments the immune system to induce inflammation, applied over 4-16 weeks, can lead to a less robust inflammatory response that also utilizes necrosis in subacute and chronic AK management.\textsuperscript{14,22,23} However, these mechanisms that utilize necrosis can induce moderate to severe local skin reactions (LSR), including varying degrees of painful erythema, crusting, and erosions in up to 90\% of patients that may last several weeks.\textsuperscript{3,24,25} Conversely, agents that are thought to treat AKs by promoting apoptosis, such as diclofenac (which inhibits epidermal COX-2 expression) lead to negligible LSRs, with the caveat that treatment requires 60-90 days of continual twice daily application.\textsuperscript{3,22,26,27}

**Barriers to Effective Field Therapy For AK**

While there are few head-to-head definitive trials to assess the relative (real-world) efficacy of various field therapies, recent meta-analyses have suggested there is a hierarchy of AK treatment efficacy.\textsuperscript{3,14,22} Therapeutic agents that induce more inflammation (and LSRs) tend to have greater efficacy. Unfortunately, prior studies have also demonstrated that patients are more than willing to tolerate increased risk of developing skin cancer and potential improvements in the appearance of their skin if it means minimizing the inconvenience of treatment by reducing the 1) severity of local skin reactions, 2) length/frequency of treatment, and 3) eliminating systemic symptoms.\textsuperscript{28} Given current available patient-applied home therapies, selecting an optimal agent requires balancing ideal efficacy with potential patient non-adherence with treatment application.

\begin{figure}
\centering
\includegraphics[width=\textwidth]{apoptosis_necrosis.png}
\caption{Apoptosis versus necrosis. Agents such as diclofenac and tirbanibulin induce apoptosis which minimize inflammation and local skin reactions relative to necrosis-induced inflammation from 5-fluorouracil or ingenol mebutate.}
\end{figure}
Choosing a regimen is further complicated when considering the chronic nature of actinic damage and AKs. Given the accumulated chronic actinic damage will only produce more AKs (and other skin cancers) with time demanding prolonged recurrent (and necessary) treatment, dermatologists must also consider how a patient’s experience with treatment will affect their adherence to future therapies, and therefore the overall, long-term outcomes associated with each regimen.

**Advancements in Patient-Applied Treatment for Actinic Keratoses**

Studies suggest that shorter course therapies\(^1^6\) that are less cumbersome\(^2^9\) may be more practical for patients and result in improved adherence, and therefore, improved real-world efficacy. Studies have attempted to combine available therapies in hopes of synergistically improving efficacy and reducing duration/frequency of application.\(^3^0\) However, combinations such as 5-FU and calcipotriene, though potentially more efficacious than 5-FU alone based on the limited data available, also lead to increased rates of intolerable, dose-limiting LSRs.\(^3^0\)

Advances in our understanding of keratinocyte dysplasia have yielded new small molecules capable of inducing apoptosis with minimal inflammation.\(^3^1,3^2\) In vitro studies have demonstrated that KX2-391 (tirbanibulin) specifically targets rapidly dividing cells and, by reversible-binding of microtubules essential to cellular division, prevents polymerization of tubulin thereby leading to cell-cycle arrest and apoptosis.\(^3^1,3^2\) Tirbanibulin may also exert anti-tumor activity by disrupting a non-receptor tyrosine kinase, the proto-oncogene Src kinase.\(^3^1\)

Clinical trials have shown after only 5 consecutive days of daily tirbanibulin application to the face and scalp, participants noticed continued AK clearance through day 57 with 40-50% with 100% clearance.\(^3^3-3^5\) At 12-month follow up, not only were there no notable adverse effects, but 42% of participants had no recurrence of originally treated AKs.\(^3^4,3^5\) Perhaps more importantly from an adherence standpoint, studies have shown that LSRs were mild-moderate, peaked within 8 days of first application and resolved entirely within 15-29 days.\(^3^3-3^5\) Taken together these data suggest inhibition of tubulin polymerization provides an efficacious way to treat AKs that also mitigates unpleasant adverse effects of contemporary AK treatments and its shorter course may also further improve adherence to therapy.

**The Importance of Actinic Keratosis Therapy and Patient Counseling**

Studies have also demonstrated the importance of the semantics and wording used during patient counseling had a significant effect in patients’ decision-making regarding AK treatment.\(^3^6\) A significantly larger proportion of participants opted for treatment when told “AKs are precancers” or had the potential for malignant growth.
transformation compared to when were more optimistically counseled by highlighting the chance of regression.\textsuperscript{36}

More recent meta-analyses of field therapies have determined there may in fact be a hierarchy of efficacy.\textsuperscript{3,14} It is important that physicians are aware of both the efficacy of treatment and severity of local skin reactions and other adverse events so that they can provide focused counseling for patients. Dermatologists may consider off-label modifications and adjunctive therapies (such as steroidal and non-steroidal anti-inflammatory agents, moisturizers and emollients, topical antibiotics, and anti-pruritic agents) to mitigate LSRs with the caveat that there is limited evidence for their use.\textsuperscript{37} By being able to combine evidence-based regimens with patient-centered values, dermatologists may potentially maximize long-term compliance and therefore achieve (near-)ideal outcomes regarding AK care.\textsuperscript{38}

### CONCLUSION

AKs are a chronic condition with a still poorly defined potential for progression into invasive SCC. Because of the overall chronic nature of AKs and actinic damage, adequate treatment requires a combination of recurrent Dermatologist-administered office treatment and continual patient-applied home therapies. To achieve ideal outcomes, Dermatologists must understand the value of shorter course therapies and their positive impact on adherence and be well-versed in the mechanisms, efficacy and adverse events associated with treatment options so they may best counsel and educate patients as well as devise regimens that address individualized patient concerns. In this way, Dermatologists can potentially maximize adherence to therapy and improve long-term patient outcomes.

Conflict of Interest Disclosures: JWM has no relevant disclosures. JDR serves as a research investigator, speaker, and consultant for Almirall, Bausch Health (Ortho Dermatology), and Sun Pharma and a consultant for Biofrontera. NB has affiliations with Abbvie, Almirall, Biofrontera, BMS, BI, EPI Health, Ferndale, Foamix, Galderma, InCyte, ISDIN, J&J, LaRoche-Posay, Leo, Lilly, Ortho, Pfizer, P&G, Regeneron, Sanofi, SunPharma, Vyne, and Vyome. DSR served as an advisory board member for Almirall, Inc.

Funding: This study received funding from an unrestricted educational grant from Almirall, Inc.

### References:

1. R Ahn CS, Culp L, Huang WW, Davis SA, Feldman SR. Adherence in dermatology. J Dermatolog Treat. 2017 Mar;28(2):94-103. doi: 10.1080/09546634.2016.1181256. Epub 2016 May 15. PMID: 27180785.

2. Lee IA, Maibach HI. Pharmionics in dermatology: a review of topical medication adherence. Am J Clin Dermatol. 2006;7(4):231-6. doi: 10.2165/00128071-200607040-00004. PMID: 16901183.

3. Neri L, Peris K, Longo C, Calvieri S, Frascione P, Parodi A, Elbenschulz L, Bottoni U, Pellacani G; Actinic Keratosis - TRoute ment Adherence INitiative (AK-TRAIN) study group. Physician-patient communication and patient-reported outcomes in the actinic keratosis treatment adherence initiative (AK-TRAIN): a multicenter, prospective, real-life study of treatment satisfaction, quality of life and adherence to topical field-directed therapy for the treatment of actinic keratosis in Italy. J Eur Acad Dermatol Venereol. 2019 Jan;33(1):93-107. doi: 10.1111/jdv.15142. Epub 2018 Jul 8. PMID: 29920789.

4. Kopasker, D., Kwiatkowski, A., Matin, R.N., Harwood, C.A., Ismail, F., Lear, J.T., Thomson, J., Hasan, Z., Wali, G.N., Milligan, A., Crawford, L., Ahmed, I., Duffy, H., Proby, C.M., Allanson, P.F., 2019. Patient preferences for topical treatment of actinic keratoses: a discrete-choice experiment. British Journal of Dermatology 180, 902–909.. doi:10.1111/bjd.16801
5. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, Gould C, Gemmen E, Dall T; American Academy of Dermatology Association; Society for Investigative Dermatology. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006 Sep;55(3):490-500. doi: 10.1016/j.jaad.2006.05.048. PMID: 16908356.

6. Yeung H, Baranowski ML, Swerlick RA, Chen SC, Hemingway J, Hughes DR, Duszak R Jr. Use and Cost of Actinic Keratosis Destruction in the Medicare Part B Fee-for-Service Population, 2007 to 2015. JAMA Dermatol. 2018 Nov 1;154(11):1281-1285. doi: 10.1001/jamadermatol.2018.3086. PMID: 30326488; PMCID: PMC6248125.

7. Filosa A, Filosa G. Actinic keratosis and squamous cell carcinoma: clinical and pathological features. G Ital Dermatol Venereol. 2015;150(3):236-240. doi: 10.1007/s10017-015-2246-x.

8. Marks R, Foley P, Goodman G, Hage BH, Selwood TS. Spontaneous remission of solar keratoses: the case for conservative management. Br J Dermatol. 1986;115:649-655.

9. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet. 1988;1:795-797.

10. Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspective. Arch Dermatol. 1991 Jul;127(7):1029-31. PMID: 2064402.

11. Marks R. The role of treatment of actinic keratoses in the prevention of morbidity and mortality due to squamous cell carcinoma. Arch Dermatol. 1991 Jul;127(7):1031-3. PMID: 2064403.

12. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol. 2000;42(1 Pt 2):23-4.

13. de Oliveira ECV, da Motta VRC, Pantoja PC, Ilha CSO, Magalhães RF, Galadari H, Leonard GR. Actinic keratosis - review for clinical practice. Int J Dermatol. 2019 Apr;58(4):400-407. doi: 10.1111/ijd.14147. Epub 2018 Aug 2. PMID: 30070357.

14. Jansen MHE, Kessels JPHM, Nelemans PJ, Kouloubis N, Arits AHMM, van Peit HPA, Quaedvlieg PJF, Essers BAB, Steijlen PM, Kelleners-Smeets NWJ, Mosterd K. Randomized Trial of Four Treatment Approaches for Actinic Keratosis. N Engl J Med. 2019 Mar 7;380(10):935-946. doi: 10.1056/NEJMoa1811850. PMID: 30855743.

15. Dianzani C, Conforti C, Giuffrida R, Corneli P, di Meo N, Farinazzo E, Moret A, Magaton Rizzi G, Zalaudek I. Current therapies for actinic keratosis. Int J Dermatol. 2020 Jun;59(6):677-684. doi: 10.1111/ijd.14767. Epub 2020 Feb 3. PMID: 32012240.

16. Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence. 2013 Dec 17;8:35-41. doi: 10.2147/PPA.S47126. PMID: 24379656; PMCID: PMC3872140.

17. Guenther ST, Hurwitz RM, Buckel LJ, Gray HR. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: a clinicopathologic correlation. J Am Acad Dermatol. 1999;41(3 Pt 1):443-8.

18. Keller B, Braathen LR, Marti HP, Hunger RE. Skin cancers in renal transplant recipients: a description of the renal transplant cohort in Bern. Swiss Med Wkly. 2010 Jul 15;140:w13036. doi: 10.4414/swm.2010.13036. PMID: 20652847.

19. Foley P, Stockfleth E, Peris K, Basset-Seguin N, Cerio R, Antonio Sanches J, Guillen C, Farrington E, Lebwohl M. Adherence to topical therapies in actinic keratosis: A literature review. J Dermatol Treat. 2016 Nov;27(6):538-545. doi: 10.1080/09546634.2016.1178372. Epub 2016 May 10. PMID: 27161045.

20. Berker, D., McGregor, J.M., Mohd Mustapa, M.F., Exton, L.S., Hughes, B.R., Mchenry, P.M., Gibbon, K., Buckley, D.A., Nasr, I., Duarte Williamson, C.E., Swale, V.J., Leslie, T.A., Mallon, E.C., Wakelin, S., Ungureanu, S., Hunasehally, R.Y.P., Cork, M., Johnston, G.A., Natkunarajah, J., Worsnop, F.S., Chiang, N., Donnelly, J., Saunders, C., Brian, A.G., 2017. British Association of Dermatologists’ guidelines for the care of patients with actinic keratosis 2017. British Journal of Dermatology 176, 20–43.

21. Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol. 2013 Jan;68(1 Suppl 1):S10-9. doi: 10.1016/j.jaad.2012.09.053. PMID: 23228301.

22. Gupta AK, Paquet M. Network meta-analysis of the outcome ‘participant complete clearance’ in nonimmunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol. 2013 Aug;169(2):250-9. doi: 10.1111/bjd.12343. PMID: 23550994.
23. AAD. Actinic keratoses: diagnosis and treatment. 2019. https://www.aad.org/public/diseases/scaly-skin/actinic-keratosis

24. Cerio R. The importance of patient-centred care to overcome barriers in the management of actinic keratosis. J Eur Acad Dermatol Venereol. 2017 Mar;31 Suppl 2:17-20. doi: 10.1111/jdv.14091. PMID: 28263022.

25. Hansen JB, Larsson T, Dunkelly-Allen N, Veverka KA, Feldman SR. Real-World Effectiveness and Safety of Field- and Lesion-Directed Treatments for Actinic Keratosis. J Drugs Dermatol. 2020 Aug 1;19(8):756-762. doi: 10.36849/JDD.2020.5123. PMID: 32804451.

26. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, Pentland AP. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis. 1998 May;19(5):723-9. doi: 10.1093/carcin/19.5.723. PMID: 9635856.

27. Elmets, C.A., Ledet, J.J., Athar, M., 2014. Cyclooxygenases: Mediators of UV-Induced Skin Cancer and Potential Targets for Prevention. Journal of Investigative Dermatology 134, 2497–2502. doi:10.1038/jid.2014.192.

28. Kopasker, D., Kwiatkowski, A., Matin, R.N., Harwood, C.A., Ismail, F., Lear, J.T., Thomson, J., Hasan, Z., Wali, G.N., Milligan, A., Crawford, L., Ahmed, I., Duffy, H., Proby, C.M., Allanson, P.F., 2019. Patient preferences for topical treatment of actinic keratoses: a discrete-choice experiment. British Journal of Dermatology 180, 902–909. doi:10.1111/bjd.16801.

29. Werner RN, Jacobs A, Rosumek S, Erdmann R, Sporbeck B, Nast A.Methods and Results Report - Evidence and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatol-ogy Forum.J Eur Acad Dermatol Venereol 2015;29: e1–e66

30. Cunningham TJ, Tabacchi M, Eliane JP, Tuchayi SM, Manivasagam S, Mirzaalinn H, Turkoz A, Kopan R, Schaffer A, Saavedra AP, Wallendorf M, Cornelius LA, Demehri S. “Randomized trial of calcipotriol combined with 5-fluorouracil for skin cancer precursor immunotherapy,” J Clin Invest. 2017 Jan 3;127(1):106-116. doi: 10.1172/JCI89820. Epub 2016 Nov 21.

31. Smolinski, M.P., Bu, Y., Clements, J., Gelman, I.H., Hegab, T., Cutler, D.L., Fang, J.W.S., Fetterly, G., Kwan, R., Barnett, A., Lau, J.Y.N., Hangauer, D.G., 2018. Discovery of Novel Dual Mechanism of Action Src Signaling and Tubulin Polymerization Inhibitors (KX2-391 and KX2-361). Journal of Medicinal Chemistry 61, 4704–4719. doi:10.1021/acs.jmedchem.8b00164

32. Niu L, Yang J, Yan W, Yu Y, Zheng Y, Ye H, Chen Q, Chen L. Reversible binding of the anticancer drug KXO1 (tirbanibulin) to the colchicine-binding site of β-tubulin explains KXO1's low clinical toxicity. J Biol Chem. 2019 Nov 29;294(48):18099-18108. doi: 10.1074/jbc.RA119.010732. Epub 2019 Oct 18. PMID: 31628188; PMCID: PMC6885616.

33. Blauvelt, A., Kepmers, S., Forman, S., Lain, E., & Bruce, S. (2020). Tirbanibulin Ointment 1%, a Novel Inhibitor of Tubulin Polymerization and Src Kinase Signaling , for the Treatment of Actinic Keratosis (AK): Results from Two Pivotal Phase III Studies. SKIN The Journal of Cutaneous Medicine, 4(5), s63. https://doi.org/10.25251/skin.4 supp.62

34. Blauvelt, A., Kepmers, S., Schlesinger, T., Lain, E., Wang, H., Cutler, D., Lebwohl, M., Fang, J., & Kwan, R. (2020). Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Pooled Data from Two Phase 3 Studies. SKIN The Journal of Cutaneous Medicine, 4(6), s121. https://doi.org/10.25251/skin.4 supp.121

35. Blauvelt A, Kepmers S, Lain E, Schlesinger T, Tyring S, Forman S, Ablon G, Martin G, Wang H, Cutler DL, Fang J, Kwan MR: Phase 3 Tirbanibulin for Actinic Keratosis Group. Phase 3 Trials of Tirbanibulin Ointment for Actinic Keratosis. N Engl J Med. 2021 Feb 11;384(6):512-520. doi: 10.1056/NEJMoa2024040. PMID: 33567191.

36. Berry, K., Butt, M., Kirby, J.S., 2017. Influence of Information Framing on Patient Decisions to Treat Actinic Keratosis. JAMA Dermatology 153, 421.. doi:10.1001/jamadermatol.2016.5245

37. Freeman, S., Bettencourt, M., Corlliss, M., Dunkelly-Allen, N, & Veverka, K. A. (2020). Evaluation of Different Approaches in Managing Local Skin Reactions With the Use of Ingenol Mebutate 0.015% and 0.05% During the Treatment of Actinic Keratosis. J Clin Invest. 2020 Feb 11;134(6):512-520. doi: 10.1056/NEJMoa2024040. PMID: 33567191.

38. Grada, A., Feldman, S.R., Bragazzi, N.L., Damiani, G., 2021. Patient-reported outcomes of topical therapies in actinic keratosis: A systematic review. Dermatologic Therapy.. doi:10.1111/dth.14833